ELB245 for 12 Weeks Versus 4mg Tolterodine in Patients With Incontinent Overactive Bladder (OAB)
This study has been terminated.
(side effect profile did not match expectations)
Sponsor:
elbion AG
Information provided by:
elbion AG
ClinicalTrials.gov Identifier:
NCT00439192
First received: February 22, 2007
Last updated: August 7, 2007
Last verified: August 2007
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study has been terminated. |
|---|---|
| Study Completion Date: | August 2007 |
| Estimated Primary Completion Date: | No date given |